Category Archives: Lose Weight Fast

Combination of Once-Weekly XPOVIO (selinexor), Once-Weekly Velcade (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade plus Dexamethasone (Vd) Regimen

47% Increase in Median PFS on SVd versus Vd

Regulatory Submission Planned in 2Q 2020; Data to be Submitted for Presentation at Upcoming Medical Meetings

Management to Host Conference Call Today at 8:30 AM ET

NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO (selinexor) in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS). The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio=0.70; p=0.0066). There were no new safety signals on the SVd arm and there was no imbalance in deaths between the two arms in the study. The full top-line data will be submitted for presentation at upcoming medical meetings.

We are thrilled to report these highly significant top-line results from the BOSTON study, the first randomized Phase 3 trial to demonstrate clinically and statistically significant activity of once-weekly XPOVIO in combination with a current standard of care treatment in patients with myeloma after one to three prior therapies, said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. In the study, patients on the SVd regimen lived 47% longer without their disease worsening, which we believe represents an important improvement in the treatment of patients with relapsed or refractory multiple myeloma. We plan to submit the full data set for presentations at upcoming medical meetings to share the results with the medical community. We also intend to submit these data as quickly as possible to the U.S. Food and Drug Administration (FDA) as part of a supplemental New Drug Application seeking to expand the approved indication for XPOVIO into second line treatment for patients with relapsed or refractory multiple myeloma. If approved, the SVd regimen would be the first and only FDA-approved combination drug regimen that includes once-weekly Velcade therapy for relapsed myeloma.

XPOVIO received accelerated approval from the FDA on July 3, 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Karyopharm expects to submit data from the Phase 3 BOSTON study to serve as this confirmatory trial. The full Prescribing Information for XPOVIO is available at http://www.XPOVIO.com.

About the BOSTON Study

BOSTON is a Phase 3 randomized, active comparator-controlled, open-label, multicenter study that is designed to compare the efficacy, safety and certain health-related quality of life (HR-QoL) parameters of once-weekly XPOVIO (selinexor) in combination with once-weekly Velcade (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade plus low-dose dexamethasone (Vd) in adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. The BOSTON study enrolled approximately 402 patients. The primary endpoint of the study is progression-free survival (PFS) and key secondary endpoints include overall response rate (ORR), among others. Additionally, the BOSTON study allows for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease. The BOSTON study is being conducted at over 150 clinical sites internationally.

Vd is a standard therapy for previously treated patients with multiple myeloma that is given by injection twice-weekly. Unlike other drugs used to treat multiple myeloma, selinexor is taken orally. Patients randomized to the SVd arm received selinexor (100mg once-weekly), Velcade (1.3 mg/m2 once-weekly given subcutaneously) and dexamethasone (40mg weekly). Patients randomized to the Vd arm received Velcade (twice-weekly) plus low-dose dexamethasone (standard therapy given on the recommended schedule).

Conference Call Information

Karyopharm will host a conference call today, Monday, March 2, 2020, at 8:30 a.m. Eastern Time, to discuss the top-line results from the BOSTON study. To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference 3515858. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Multiple Myeloma

According to the National Cancer Institute (NCI), multiple myeloma is the second most common blood cancer in the U.S. with more than 32,000 new cases each year and over 130,000 patients living with the disease. Despite recent therapeutic advances, there is currently no cure and most patients disease will typically progress following treatment with currently available therapies. According to the NCI, nearly 13,000 deaths due to multiple myeloma were expected in the U.S. in 2019.

About XPOVIO (selinexor)

XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. Karyopharm received accelerated U.S. Food and Drug Administration (FDA) approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor. A supplemental New Drug Application was recently submitted to the FDA seeking accelerated approval for selinexor as a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and selinexor has received Fast Track and Orphan designation from the FDA for this patient population. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), as a potential backbone therapy in combination with approved therapies (STOMP), in liposarcoma (SEAL) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharm's clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at http://www.clinicaltrials.gov.

IMPORTANT SAFETY INFORMATION

Thrombocytopenia

XPOVIO can cause thrombocytopenia, leading to potentially fatal hemorrhage. Thrombocytopenia was reported as an adverse reaction in 74% of patients, and severe (Grade 3-4) thrombocytopenia occurred in 61% of patients treated with XPOVIO. The median time to onset of the first event was 22 days. Bleeding occurred in 23% of patients with thrombocytopenia, clinically significant bleeding occurred in 5% of patients with thrombocytopenia and fatal hemorrhage occurred in <1% of patients.

Monitor platelet counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia

XPOVIO can cause neutropenia, potentially increasing the risk of infection. Neutropenia was reported as an adverse reaction in 34% of patients, and severe (Grade 3-4) neutropenia occurred in 21% of patients treated with XPOVIO. The median time to onset of the first event was 25 days. Febrile neutropenia was reported in 3% of patients.

Obtain neutrophil counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF). Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity

Gastrointestinal toxicities occurred in patients treated with XPOVIO.

Nausea/Vomiting

Nausea was reported as an adverse reaction in 72% of patients, and Grade 3 nausea occurred in 9% of patients treated with XPOVIO. The median time to onset of the first nausea event was 3 days.

Vomiting was reported in 41% of patients, and Grade 3 vomiting occurred in 4% of patients treated with XPOVIO. The median time to onset of the first vomiting event was 5 days.

Provide prophylactic 5-HT3 antagonists and/or other anti-nausea agents, prior to and during treatment with XPOVIO. Manage nausea/vomiting by dose interruption, reduction, and/or discontinuation. Administer intravenous fluids and replace electrolytes to prevent dehydration in patients at risk. Use additional anti-nausea medications as clinically indicated.

Diarrhea

Diarrhea was reported as an adverse reaction in 44% of patients, and Grade 3 diarrhea occurred in 6% of patients treated with XPOVIO. The median time to onset of diarrhea was 15 days.

Manage diarrhea by dose modifications and/or standard anti-diarrheal agents; administer intravenous fluids to prevent dehydration in patients at risk.

Anorexia/Weight Loss

Anorexia was reported as an adverse reaction in 53% of patients, and Grade 3 anorexia occurred in 5% of patients treated with XPOVIO. The median time to onset of anorexia was 8 days.

Weight loss was reported as an adverse reaction in 47% of patients, and Grade 3 weight loss occurred in 1% of patients treated with XPOVIO. The median time to onset of weight loss was 15 days.

Monitor patient weight at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Manage anorexia and weight loss with dose modifications, appetite stimulants, and nutritional support.

Hyponatremia

XPOVIO can cause hyponatremia; 39% of patients treated with XPOVIO experienced hyponatremia, 22% of patients experienced Grade 3 or 4 hyponatremia. The median time to onset of the first event was 8 days.

Monitor sodium level at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels. Treat hyponatremia per clinical guidelines (intravenous saline and/or salt tablets), including dietary review. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Infections

In patients receiving XPOVIO, 52% of patients experienced any grade of infection. Upper respiratory tract infection of any grade occurred in 21%, pneumonia in 13%, and sepsis in 6% of patients. Grade 3 infections were reported in 25% of patients, and deaths resulting from an infection occurred in 4% of patients. The most commonly reported Grade 3 infections were pneumonia in 9% of patients, followed by sepsis in 6%. The median time to onset was 54 days for pneumonia and 42 days for sepsis. Most infections were not associated with neutropenia and were caused by non-opportunistic organisms.

Neurological Toxicity

Neurological toxicities occurred in patients treated with XPOVIO.

Neurological adverse reactions including dizziness, syncope, depressed level of consciousness, and mental status changes (including delirium and confusional state) occurred in 30% of patients, and severe events (Grade 3-4) occurred in 9% of patients treated with XPOVIO. Median time to the first event was 15 days.

Optimize hydration status, hemoglobin level, and concomitant medications to avoid exacerbating dizziness or mental status changes.

Embryo-Fetal Toxicity

Based on data from animal studies and its mechanism of action, XPOVIO can cause fetal harm when administered to a pregnant woman. Selinexor administration to pregnant animals during organogenesis resulted in structural abnormalities and alterations to growth at exposures below those occurring clinically at the recommended dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

ADVERSE REACTIONS

The most common adverse reactions (incidence 20%) are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

The treatment discontinuation rate due to adverse reactions was 27%; 53% of patients had a reduction in the XPOVIO dose, and 65.3% had the dose of XPOVIO interrupted. The most frequent adverse reactions requiring permanent discontinuation in 4% or greater of patients who received XPOVIO included fatigue, nausea, and thrombocytopenia. The rate of fatal adverse reactions was 8.9%.

Please see XPOVIO Full Prescribing Information available at http://www.XPOVIO.com.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharms lead compound, XPOVIO (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. An MAA for selinexor is also currently under review by the EMA for the same indication. The Company recently submitted a New Drug Application to the FDA seeking approval for XPOVIO in patients with DLBCL. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharms expectations relating to XPOVIO for the treatment of patients with heavily pretreated multiple myeloma or relapsed or refractory diffuse large B-cell lymphoma; commercialization of XPOVIO or any of its drug candidates and the commercial performance of XPOVIO; submissions to, and the review and potential approval of selinexor by, regulatory authorities, including the anticipated availability of data to support such submissions, timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways; and the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, especially selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO; that regulators will agree that selinexor qualifies for conditional approval in the E.U. as a result of data from the STORM study or confirmatory approval in the U.S. or EU based on the BOSTON study in patients with relapsed or refractory multiple myeloma, or accelerated approval in the U.S. for patients with relapsed or refractory DLBCL as a result of data from the SADAL study, or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharms drug candidates that receive regulatory approval; the ability to retain regulatory approval of XPOVIO or any of Karyopharms drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2020, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Velcade is a registered trademark of Takeda Pharmaceutical Company Limited

Contacts:

Investors: Karyopharm Therapeutics Inc. Ian Karp, Vice President, Investor and Public Relations857-297-2241 | ikarp@karyopharm.com

Media:

FTI ConsultingSimona Kormanikova or Robert Stanislaro212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

The rest is here:
Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple...

People with severe mental illness, such as psychosis or bipolar disorder, live on average 15-20 years less than the average person which is one of the key health inequalities people face in the UK and worldwide. But although programmes and initiatives have been created that aim to help people with severe mental illnesses take control of their health, these targeted interventions often fall short.

One major reason that people with severe mental illness live shorter lives on average, is because theyre more likely to suffer from physical health conditions. Not only does research show theyre twice as likely to have obesity, diabetes, or chronic obstructive pulmonary disease, theyre also 1.5 times more likely than the average person to have heart disease.

But socioeconomic status also has a major effect on how likely a person is to develop these conditions, including those with severe mental illnesses. Socioeconomic disadvantage such as having lower income, receiving less education, or living in a deprived area are all shown to be causes in developing chronic health conditions.

Not only does socioeconomic disadvantage appear to be a risk factor for developing mental disorders, research also shows that people with severe mental illness are 3.6 times more likely to live in the most socially deprived areas than the average.

Studies show that people living in deprived areas are also four to five times more likely to engage in unhealthy behaviours such as alcohol misuse, smoking, and having an unhealthy diet. All of these can lead to a range of long-term physical conditions, such as cancer or cardiovascular disease. On top of this, people with severe mental illness are also more likely to engage in risky behaviours that can lead to severe health complications.

Around 40% of adults with severe mental illness smoke, compared with just 15% of people in the general population. Theyre also three to four times more likely to misuse alcohol or drugs. However, these behaviours might reflect attempts to self-medicate. For example, people sometimes choose to smoke after starting new medication in order to counter the drugs effects on their metabolism, and decrease their appetite. Research does show that nicotine can increase how quickly your body processes antipsychotics, potentially reducing the intensity of their side-effects.

Read more: Having a severe mental illness often means dying before your time

People with severe mental illness are also more likely to have an unhealthy diet. This might be because medications can affect appetite and energy levels. One study found that people gained 12kg on average in the first 24 months after their diagnosis.

National guidance has been created which outlines how to help patients with mental illnesses improve their health. However, studies have shown large variations in whether these interventions are being offered by healthcare providers.

Its unclear why these differences exist, but earlier research suggested staff members didnt have enough support to follow these guidelines and put them into action. The lack of coordination between physical and mental healthcare systems might also be to blame.

Despite these guides, it can still be difficult to support people with severe mental illness in improving their health. Research found that healthcare staff didnt feel confident enough to support people with severe mental illness in quitting smoking. Many healthcare workers said they were concerned about the impact quitting would have on the patients mental health. Many people with severe mental illness even say smoking brings them pleasure, despite the long-term health risks.

But recent research shows that methods for quitting smoking are as effective in people with severe mental illness as the general population. And, tailored interventions that provided extra support to people with schizophrenia and bipolar disorder (such as longer sessions to prepare for quitting, and home visits) appeared to improve quitting rates.

Managing weight is also key in reducing early risk of death from health complications. One review found that nutrition interventions including group nutrition classes, help with shopping, and cooking classes reduced weight and body mass index. But attempts to replicate these results have failed in larger, high-quality trials for reasons that remain unclear. Weight loss can be challenging, as people may not know how to prepare healthy meals or exercise properly. It may also be difficult for people to travel to get fresh foods or take part in an exercise class while managing their mental health.

Personalised approached might be more effective, as unhealthy behaviours can cluster together. For example, if a person misuses alcohol, they might smoke too. Targeting these behaviours at the same time might lead to greater improvements than targeting them alone but the reverse might also be the case. For example, one study found that people who improved their diet or increased their level of physical activity were less likely to quit smoking.

New approaches such as analysing data collected by treatment services to track progress, using digital technology during interventions, and even promoting interaction with nature are some ways that might help improve the physical health of those with severe mental illness. People with severe mental illness are also increasingly working alongside researchers as partners to provide input and share their experiences rather than simply being study participants that are observed to collect data. This is important for making sure research delivers meaningful evidence that has real-world use and benefits.

But the problem with the severe mental illness label is that most studies have combined data on physical health risks for different mental health conditions (including psychosis, schizophrenia, and bipolar disorder). This fails to examine whether different conditions carry different risks.

It will be important for future research to work alongside participants with severe mental illness during high-quality trials to better understand what methods can help tackle this major health inequality.

Go here to read the rest:
People with severe mental illness live shorter lives but the solution isn't simple - The Conversation UK

Girls Wrestling

East Haven sophomore Zayuri Castaneda earned a first-place finish at the inaugural Girls Wrestling Invitational last weekend. Zayuri took the gold in the 235-pound division while representing the Yellowjackets at the tournament, which was held at Floyd Little Athletic Center on Feb. 28 and 29.

Castaneda notched two pinfall victories on her way to winning her round-robin bracket at the invitational. In her first match, Castaneda pinned Natalia Morris of Trumbull in just 52 seconds. Castaneda went on to pin Ruby Camejo from New Haven at the 5:22 mark in her second bout.

Camejo then defeated Morris on a pin in the next contest. With her record of 2-0, Castaneda was crowned the first champion of the 235-pound division at the Girls Invitational.

Boys Wrestling

The Yellowjackets saw five athletes compete when the State Open Championship took place at Floyd Little Athletic Center on Feb. 28 and 29. East Haven scored 11 points to finish in a tie for 55th place at the meet.

Senior Alec DiVito won his first matchup via 3-2 decision before losing by 8-0 major decision in the quarterfinals of the 132-pound division. DiVito won his first consolation match by 7-3 decision and then lost his second match on 4-2 decision. DiVito entered the State Open on the heels of a first-place finish the 132-pound weight class at the Class M State Championship.

Senior Fabricio Bugatti won his opening bout of the 160-pound bracket by a 6-3 decision, after which he took a 5-0 loss in the second round. In his first consolation match, Bugatti dropped a 5-3 decision.

In the 126-pound division, junior Matt DiVito lost his first match by a 5-3 decision. DiVito won his first two consolation bouts by 8-4 and 13-9 decisions, respectively, then lost a 7-0 major decision in his next contest.

Senior Tanner DiVito came into the State Open after winning the 138-pound division at the Class M State Championship. DiVito lost a 10-8 decision in his first match at the Open, then came back to win an 11-3 major decision in his first consolation matchup. In his next bout, DiVito lost on a 3-0 decision.

Junior Tyler Kruse took a 5-1 loss in his opening bout. Kruse later lost a 9-1 major decision in his first consolation match.

Boys Ice Hockey

The East Haven co-op ice hockey team took three defeats during the last week of the regular to put its record at 8-12 entering the playoffs.

On Feb. 24, the Yellowjackets took a 5-2 home loss versus Guilford at Patsy DiLungo Ice Rink. East Haven had 2-0 lead after the first period before allowing the Indians to score five unanswered goals. Juniors Dave Amatruda and Cory Benni were the Yellowjackets goal scorers in the game.

Two days later, the Yellowjackets lost a 2-1 contest against Branford at Northford Ice Pavilion. Branford scored first, but East Haven quickly tied the game on a goal by Benni. The Hornets netted the go-ahead goal at the 5:29 mark of the second period and went on to get the 2-1 victory.

Then on Feb. 29, East Haven took an 8-2 defeat to Sheehan in its regular-season finale at Choate Ice Rink.

With their record of 5-2 in divisional play, the Yellowjackets have earned the No. 4 seed in the SCC/SWC Division II State Tournament. East Haven is playing top-seeded Branford in semifinal game at Bennett Rink on Thursday, March 5 at 7:30 p.m. With a victory, East Haven would face the winner of No. 2 seed Hand and No. 3 North Haven in the championship game at Bennett Rink at 4 p.m. on Saturday, March 7.

Following the conference tourney, East Haven will compete in the Division II State Tournament beginning with first-round action on Monday, March 9.

Boys Basketball

The Yellowjackets hosted Seymour for their last regular-season game on Feb. 27. East Haven dropped a 74-51 decision against the Wildcats to finish with a record of 4-16 on the year.

Boys Swimming and Diving

The Greater New Haven Warriors (GNH) boys swimming and diving team clinched the SCC Division 2 title by earning a home victory versus divisional opponent Sheehan in its regular-season finale on Senior Night. On Feb. 24, the Warriors hosted Sheehan and prevailed 100-70 at Walter Gawrych Community Pool to win the crown with a record of 6-0 in divisional meets. GNH finished with an overall mark of 8-2 for the regular season.

Later in the week, North Haven freshman Christian Butler earned a medal by finishing in sixth place at the SCC Diving Championship on behalf of the Warriors.

The Warriors honored North Haven student Stephen Borrelli and fellow senior captains Aidan Henry and Evan Laughlin of Guilford as part of their Senior Night festivities prior to their meet against Sheehan. Borrelli swam a lifetime-best time of 2:06.48 in the 200 freestyle in the victory. Henry went undefeated in the 50, 100, 200, and 500 freestyles during the regular season.

Junior Tanner Powell swam a lifetime best of 1:02.65 in the 100 butterfly for GNH. Junior Collin Romero turned in a lifetime best of 28.43 for the 50 freestyle, while freshman Patrick Cucchiarelli did a lifetime best in the 100 freestyle (59.60) to go with a season-best in the 100 backstroke (1:09.75).

Other swimmers who recorded season-best marks were junior Dan Kamen in the 200 individual medley (2:13.52), junior Cameron Cargan in the 200 freestyle (1:58.09); freshman Aiden Cohen (24.62), freshman Lucas Espinosa (26.03), and sophomore Miguel Pearce (26.19) in the 50 freestyle; and freshman RT Trotter in the 100 butterfly (1:05.34) and 100 breaststroke (1:18.01)

Butler posted a lifetime-best score of 209.80 for a six-dive routine during the Warriors win against Sheehan. Later in the week, Butler competed at the SCC Diving Championship and claimed sixth place by scoring 321.25 points for his 11-diving performance at Sheehan High School on Feb. 28. Butler scored points that will count toward the Warriors total when they swim at the SCC Championship this week.

After SCCs, GNH will compete in the Class LL State Championship, beginning with the Diving Championship at Middletown High School on Wednesday, March 11 at 5:30 p.m. The Class LL Swimming Trials will take place at East Hartford High School on Saturday, March 14 at 11:30 p.m., and the Class LL Swimming State Championship will be held at Wesleyan University on Tuesday, March 17 at 6 p.m.

Read the original here:
Castaneda Takes 1st at Girls' Wrestling Invitational; Boys Send Five to State Open - Zip06.com

Hamilton's Ryan Bennett was the area's lone region champion on Saturday but the big news from the region action wasn't so much about who won but who lost.

Allentown's Joe Lamparelli, already a two time region champion, fell short of tying the CVC record of three region titles set by Steinert's two time state champion Brandon Cray when he lost to Middletown North's Fred Luchs 6-4 in overtime in the final of the NJSIAA/Rothman Orthopaedic Region 6 Tournament at Jackson Liberty.

At 40-6, Luchs is no slouch but considering Lamparelli came into the final at 39-0 and had defeated Luchs 9-3 in the District 22 final a week earlier, the loss had to be a disappointing one.

Lamparelli, who has just missed out on placing in the toughest weight class of the state tournament the past two years, will now face a tougher road to the elusive goal of medaling in Atlantic City. In a weight that includes several returning place winners, including last year's 113 pound state champion, Dean Peterson of St. John Vianney, the hit he is likely take in seeding from the loss will not help.

As unexpected as Lamparelli's finals defeat was, the lone area wrestler who claimed a region title also surprised as Bennett won the 170 pound championship at Region 6 after being seeded eighth in the weight.

Bennett, at 33-2 was an unlikely eighth seed but he quickly put the lie to that ranking when he knocked off the bracket's top seed, District 21 champion Brendan Newbury of Wall, 9-4 on Friday night in Jackson.

He cruised through his semifinal bout with a 12-4 decision over Burlington City's 4-seed James Ball and then completed his championship run with an 11-3 major decision in an all Mercer County final over Allentown's Paskal Miga.

Miga's path to the title match was just as littered with upset wins. The 10-seed Miga defeated 7-seed Connor Verga of Lawrence in Wednesday night's opening round and then buried 2-seed Anthony Bailey of Raritan in the first period of his Friday quarterfinal. Miga stamped his ticket to the final with a 7-3 semifinal win over 6-seed Jack Friedman of Long Branch.

In addition to Lamparelli and Miga, four other area wrestlers finished second in their regions. In Region 6, Northern Burlington's Brandon Totten avenged his surprising District 21 final loss to Wall's Cole Meyer by defeating Meyer in the semifinal at 113, 5-3. He lost in the final to top seeded and four time region championTyler Klinsky of Middletown North.

Allentown's Nick Golden also reached the final. Golden pinned his way through two rounds before falling in the final 3-2 to Red Bank Catholic's Sabino Portello, who won the championship out of the eighth seed.

Over in Region 5 at Franklin, both Princeton's James Romaine at 152 and Hopewell Valley's Christian Cacciabaudo at 220 were runners-up. While 3-seed Romaine came up short in the final in a 7-5 loss to top seed Michael McGee of Shore, he had an impressive tournament.

Romaine easily dispatched 6-seed Owen Fitzgerald of Middletown Southin the quarterfinals Friday night and then scored an impressive overtime win in the semifinals over 2-seed Anthony Romaniello of Hunterdon Central 11-10. Suffering through a late assault on top by Romaniello at the end of regulation, Romaine held on to force overtime and then parlayed a near fall in the second period of overtime to forge the victory.

Cacciabaudo, the sixth seed, was a sleeper at 220 as he surprised the weight's 3-seed, Joseph Porcaro of Sayreville 5-3 in the semifinals to earn his spot in the finals. He lost to 5-seed Michael Pavlinetz of Holmdel 7-2 in the final.

All of Hopewell's big three upper weights will be heading to Atlantic City as the two other members of the trio, 182 pounder Josh Beigman and Brian LaCross at 195 finished fourth in Region 5. Beigman, the fourth seed, had lost to top seed and eventual champion Blake Clayton of St. John Vianney in the semifinal while 5-seed La Cross lost his quarterfinal bout to 4-seed Alex Uryniak of North Hunterdon but wrestled all the way back to the consolation final.

Six other wrestlers will be heading to Atlantic City after placing fourth at Region 6. Hightstown produced three state qualifiers as Chris Stavrou at 195, Bryan Bonilla at 220 and Brenden Hansen at 285 all advanced, as did Allentown's Matt Paglia at 145 and Northern Burlington's Blake Geibel at 120.

Robbinsville's Drake Torrington caught a tough break in the seeding at 126, being stuck in the upper bracket with Freehold Boro's 1-seed Nico Messina. Still, 4-seed Torrington was able to defeat Wall's Mike Bruno 6-4 in the consolation semifinals to qualify for A.C.

Eight other area wrestlers placed at their regions but did not qualify for the state tournament. Hopewell Valley's Christian Micikas at 106 and Jacob Venezia at 113 both placed fifth at Region 5 while Northern Burlington's Brandon Rzuczek at 195 and Lawrence's Jake Dallarda at 160 and Mooamen Nasr at 285 finished fifth at Region 6.

Hightstowns Kether Thornton at 132 and Bordentowns Jason Baldorossi at 182 finished sixth in Region 6.

The rest is here:
Times of Trenton wrestling: Hamiltons Bennett wins, Allentowns Lamparelli loses in region action - nj.com

247Sports released its latest update to the Top247 Rankings for the 2021 class last week. It's one of several updates that will be made throughout the coming year with spring/summer camp evaluations, to go along with senior tape and All-American Bowl/Under Armour Game critiques that will ultimately decide the final rankings next January.

The state of Georgia is well represented in the update, with several top prospects among the Top247 at this juncture.

Here, Dawgs247 breaks down the top 10 recruits in the Peach State, according to the 247Sports Rankings.

Not a subscriber?Sign up nowto get access to everything Dawgs247 has to offer, including daily content from the largest staff covering Georgia athletics and access to the largest and most active community of Dawgs fans on the Web. Dont forget tosign up for our Dawgs247 Newsletter. Its free and a great way to get daily updates on Georgia football, basketball and more delivered straight to your inbox.Like uson Facebook.Follow uson Twitter.

Did you know Dawgs247 has a podcast? That's right folks. The Junkyard Dawgcast is available bringing you the best insight into the latest Georgia news from Rusty Mansell, Jake Rowe, and Kipp Adams. Catch the latest episoderight hereorsubscribe on iTunestoday!

Excerpt from:
These are the top 10 recruits in the state of Georgia - 247Sports

Skipping breakfast and snacking late at night could lead to a delay in the bodys ability to lose weight, new research has suggested.

If were trying to shed the pounds, we know we need to watch what we eat, how much we eat and how much we move, but according to a new study our ability to burn dietary calories could also be impacted by the time of day most of our food is consumed.

The study, published in the journalPLOS Biology,monitored the metabolism of middle-aged and older subjects in a whole-room respiratory chamber over two separate 56-hour sessions.

In each session, lunch and dinner were presented at the same times (12.30pm and 17.45pm, respectively), but the timing of the third meal differed between the two halves of the study.

Read more: The best diets for long-term health

In one of the 56-hour sessions, the additional daily meal was presented as breakfast (at 8:00) whereas in the other session, a nutritionally equivalent meal was given to the same subjects as a late-evening snack (22.00pm).

The duration of the overnight fast was the same for both sessions.

While the two sessions did not differ in the amount or type of food eaten, or in participants activity levels, the daily timing of the third meal had an impact on the amount of fat burned.

Researchers found that the late-evening snack session resulted in less fat burned when compared to the breakfast session.

Study authors said the circadian rhythm, or the body clock, is programmed to assist the body to burn fat when asleep.

As a consequence, skipping breakfast and then snacking at night could lead to a delay in the burning of the fat.

Based on their experimental observations, the researchers said the timing of meals during the day/night cycle could impact the extent to which ingested food is used versus stored.

The study team said their research could have wider implications for advising people on their eating habits, suggesting that a daily fast between the evening meal and breakfast could help optimise weight management.

Snacking late at night could have a negative impact on losing weight. (Getty)

Read more:The risks and benefits of veganism

This isnt the first time the health benefits of the overnight fast have been discussed.

Last year research suggested skippingbreakfast and eating a late dinner could lead to more serious outcomes after a heart attack.

Scientists found people who frequently bypassed brekkie and regularly ate dinner less than two hours before going to bed were far less likely to survive if they suffered a heart attack.

But there has also been some contradictory research in terms of whether eating breakfast can aid weight loss.

While eating breakfast has previously been thought to help aid weight loss, a further body of research suggests you may be better off without it.

Past studies have found aprotein-based morning meal or a bowl full ofoatsfirst thing could be the key to maintaining a steady weight and controlling your appetite later in the day.

Read more: Rosie Huntington-Whiteley reveals she doesn't eat after 6pm

But last year scientists from the Monash University in Melbourne found those who eat breakfast were found to have a higher energy consumption during the day (an average of 260 more calories) compared to those who skipped the morning meal.

Breakfast eaters also weighed, on average, almost half a kilogram more (0.44kg) compared to non-breakfast eaters.

Whats more, the scientists concluded skipping breakfast does not reduce appetite during the day, as previously thought.

The scientists werent the first to challenge the supposed link between eating breakfast and weight loss.

Followers of the popularintermittent fastingdiet will often skip breakfast in order to limit their eating window to later in the day.

See the rest here:
Skipping breakfast and snacking late at night could impact weight loss, new research suggests - Yahoo Sports

LAVALE Chapman and Associates Health Carehas addedmedical weight management services to help individuals safely lose weight and improve their health.

April Cross, family nurse practitioner, will lead the medical weight management program. In addition to being a nurse practitioner,she is a certified life coach and has completed training through the Obesity Medical Association. The goal of the CAHC Weight Management Program is not just to help patients lose weight but to teach life skills that will help patients keep the weight off permanently.

Many people are able to lose weight only to regain the weight that they lost plus a few pounds more. Yo-yo dieting, which is the repeated cycle of losing and then regaining weight, has been shown to increase risk of heart disease, diabetes and fatty liver disease.

The CAHC Weight Management Program helps individuals to understand the disease of obesity. Patients work collaboratively with the weight management team to achieve healthy lifestyle changes and weight loss. The CAHC Weight Management Program uses standards of care from the Obesity Medical Association. The program also includes a licensed therapist who is certified in cognitive behavior therapy to help individuals understand their triggers for overeating.

Chapman and Associates Health Care is an integrated practice providing both primary care and behavioral health services located in LaVale. For more information, call 240-362-7294.

Visit link:
OUTLOOK | Chapman and Associates offers weight management | Local News - Cumberland Times-News

With more than 93 million Americans believed to be affected by obesity, a collaboration of national organizations that launched Obesity Care Week is bringing it back for a sixth year, March 1 through 7. Among the objectives is to create a society that values science and clinically-based care.

Its an objective Dr. Varalakshmi Niranjan shares.

Niranjan is a UConn Health primary care physician whose expertise includes obesity medicine. She sees patients in UConn Healths West Hartford office, 65 Kane St.

Obesity is linked to more than 200 diseases and disorders, and its strain on the American health care system surpasses $425 billion, according to the Obesity Care Week organizers.

We associate obesity with disease, many that should be obvious to most of us by now, Niranjan says. Excess belly fat tops the list of risk factors that we refer to collectively as the metabolic syndrome. It is the root cause for heart disease, lipid problems, hypertension, type 2 diabetes and even things like dementia, cancer, polycystic ovarian syndrome and nonalcoholic fatty liver disease. Put another way, if we can treat or avoid obesity today, we wont have to deal with a lot of other problems tomorrow.

The designation of obese is based on a formula that takes into account a persons height and weight. This calculation yields whats known as the persons body mass index (BMI). A BMI ranging from 18.5 to 24.9 is considered normal. Less than 18.5 is considered underweight, 25 to 29.9 is considered overweight, and a BMI of 30 or greater is considered obese.

Studies have shown that a reduction of 5% to 10% of body fat helps change the metabolic disease, Niranjan says. Lifestyle change with balanced nutrition and physical activity will help achieve this.

Niranjan offers a physician-supervised weight loss program. The focus is on realistic, sustainable weight loss that treats the sick fat disease.

If you look at it as a diet, to get down to your goal weight, and then you go back to what you were doing before, youll regain the weight, Niranjan says. You may want to focus on one change, get used to it, and then add another change.

A physician-supervised approach to weight loss can lead to a better scientific understanding of weight management, and more of a focus on the long game.

Remember it is neither a sprint race nor a marathon. It is a journey, Niranjan says. I tell patients, all calories are not equal. A piece of fresh fruit and a glass of fruit juice may have similar calorie counts, but the fresh fruit is a much better use of those calories, largely because of the fiber. The numbers on the nutrition label are important, but theyre just one part of making good decisions.

Working with a physician to treat obesity may present additional options for some patients, including certain medications or surgical intervention. Bariatric surgery has specific guidelines and physicians can make a referral for appropriate patients. Medications shown to treat obesity require a prescription.

With a multi-disciplinary approach obesity can be managed effectively and complications like blood pressure, diabetes, heart disease, and joint pain can be controlled, Niranjan says. Lets work together and reverse this epidemic.

In the truest sense, Niranjan also walks the walk. Outside the clinic, she helps lead the UConn chapter of Walk With a Future Doc, which facilitates regularly scheduled free walk-and-talks with physicians, physician trainees, and members of the public. The group plans to resume the walks on the second and fourth Saturday of the month this spring.

March 4 is World Obesity Day.

The Obesity Action Coalition, the Obesity Society, the STOP Obesity Alliance, the Obesity Medicine Association, and the American Society for Metabolic and Bariatric Surgery collectively launched Obesity Care Week in 2015, to address what they describe as a lack of appropriate science and clinically-based care.

Learn more about primary care at UConn Health.

Read more here:
In the Battle With Obesity, Your Doctor is Your Ally - UConn Today

If youve relied on taking herbal supplements to aid in weight loss, a recently published study has news for you.

Researchers at the University of Sydney conducted the first worldwide study of herbal medicines for weight loss in nearly two decades. Their findings suggest there isnt enough evidence to recommend present treatments.

These findings come despite some herbal medicines showing statistically more weight loss than placebos. The weight loss was less than 5.5 pounds, meaning its not of clinical significance, according to a news release from the University of Sydney.

This finding suggests there is insufficient evidence to recommend any of these herbal medicines for the treatment of weight loss. Furthermore, many studies had poor research methods or reporting and even though most supplements appear safe for short-term consumption, they are expensive and are not going to provide a weight loss that is clinically meaningful, said lead author Dr. Nick Fuller of the University of Sydneys Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders.

Researchers conducted a systematic analysis and review published in the journal Diabetes, Obesity & Metabolism. The study reviewed the most recent global research for herbal medicines and weight loss by locating 54 randomized and controlled experiments that compared the effect of herbal medicines to placebo for weight loss in more than 4,000 participants.

Herbal medicines, or herbal supplements, are products that contain a plant or a combination of plants as the primary ingredient. Those aimed at weight loss can be composed of white kidney bean, green tea and African mango.

According to the studys authors, 1,000 weight loss dietary supplements were included on the Australian Register of Therapeutic Goods without evaluation of efficacy between 1996 and 2006.

The problem with supplements is that unlike pharmaceutical drugs, clinical evidence is not required before they are made available to the public in supermarkets or chemists, Fuller said.

The supplements can be sold and marketed to the public with sponsors defined as those who import, export or manufacture goods required to have but not necessarily provide evidence backing their claims. Just 20% of new listings are annually audited to make sure the sponsors meet the requirement, the authors noted.

The growth in the industry and popularity of these products highlights the importance of conducting more robust studies on the effectiveness and safety of these supplements for weight loss, Fuller said.

See the original post:
Study says herbal supplements may not be effective for weight loss - Greater Milwaukee Today

TIPPING the scales at 16 stone, Sarah Jones knew something in her life desperately needed to change and sprung into action.

She could only fit into size 18-20 clothes and her weight gain was making her asthma dramatically worsen.

7

However, Sarah, 52, who is from Henley-in-Arden, Warks, was given a much-needed wake-up call at a former colleague's birthday party - when her confidence dived around her slim pals.

Determined to do something about her ever-growing size, Sarah decided to join her mum at a local Slimming World group.

Sarah has since shed an impressive five stone and has finally regained her confidence.

She said: "I was determined to lose five stone.

"The unfailing encouragement and support from other members became the lifeline that helped me all the way to my target.

"Now I'm back down to a size 12, I feel glamorous again."

7

7

Sarah had first piled on the pounds after giving birth to her children Courtney and Alex.

"During my years working as a cabin crew member in my 20s, I was a size 12-14," she explained.

"But, after giving birth to my daughter Courtney, I decided not to return to the airline.

"When my son Alex came along three years later, I really struggled to lose the baby weight.

"I thought simply restricting my portions would work.

7

"I was getting so hungry each evening though that I started going to bed at the same time as the children to try to stop myself from snacking.

"But it was no way to live, so I soon gave up completely and my weight began to rise again."

However, Sarah's turning point came one evening in 2013 after getting all glammed up for a party with colleagues she had not seen in 20 years.

I hid at the back of the group every time a camera came out

And her confidence plummeted when she was finally reunited with her slim friends - and instantly felt self-conscious when the camera came out.

She said: "I'd spent ages on my hair and make-up and was wearing a black, stretchy size 18-20 dress I'd bought especially.

"It was the only one in the shop that had fitted without looking "too bad" or so I'd thought at the time.

"Now, as I caught sight of my still-slim friends, I felt really self-conscious. I hid at the back of the group every time a camera came out."

7

And as Sarah and her friends reminisced about the "good old days", she couldn't help but wonder if her pals were looking at her thinking: "She's really let herself go."

At the time Sarah was the biggest she'd ever been and her asthma was getting worse as her weight increased.

She added: "And, on a recent holiday to Spain, I'd struggled so badly to get up a hill that I thought I'd be going down it again in an ambulance."

Sarah decided she desperately needed to make a change so decided to join her mum at a local SlimmingWorld group in Claverdon, Warks in January 2014.

7

Sarah's diet before and after

BEFORE

Breakfast: Toast, cereal or McDonalds breakfast

Lunch: Supermarket meal deal with sandwich, crisps and full-fat cola

Dinner: Takeaway curry

Snacks: Doritos

AFTER

Breakfast: Porridge with blueberries, raspberries and banana

Lunch: Slimming World turkey burgers, salad and Slimming World wedges

Dinner: Slimming world curry

Snacks: Satsumas

Speaking about her first session, she said: "As I stood on the scales for the first time, my tummy was in knots. And when 16st 3lbs appeared, I couldn't believe it.

"Stepping off, I knew what my target was going to be. I was determined to lose five stone.

"Tuesday night at the group would be my night - a time to focus on me."

Sarah has credited the "unfailing encouragement and support from other members" for helping her to reach her target weight.

And she admits she never felt like she was depriving herself with the Slimming World recipes.

7

"I found Slimming World great to follow because the recipes are so nice and I didn't feel like there were things I couldn't have," Sarah added.

"I would encourage anyone to give it a go.

"My asthma is so much better since my weight loss, I now don't even use an inhaler."

Sarah enjoyedSlimming World so much that, in 2015, she became a consultant herself and now runs groups in Claverdon and Henley-in-Arden.

WEIGH TO GORevenge body mum shamed for dealbreaker legs by ex now loves 'thunder thighs'

TOP PRIZEWoman, 26, crowned Miss Great Britain after shedding HALF her body weight

massive no murOlly Murs shows off his incredible weight loss in just ONE month

Exclusive

WEIGH-HEYI was a size 24 but I've finally got my sex drive back after losing 8st in a year

TAKES THE CAKEWoman loses 10st after dream job at a food company made her balloon to 23st

SOMEONE LIKE NEWAdele weight loss - how did the singer lose weight?

WEIGHT OFFI lost 10st after piling on weight after the deaths of my parents and brother

SECRET'S OUTKerry Katona reveals how she got her new ripped six-pack & slimmed down to 9st

IRN-BRU-LIEVABLEWoman who drank 10 cans of Irn-Bru a day loses 6st after going sugar-free

She added: "Now that I'm back to a size 12 and just over 11st, getting dressed up for parties no longer means going with the only outfit that I think is "OK".

"I love nothing more than putting on a slinky dress and some sky-high heels.

"I'm as slim as I was back in my cabin-crew days and, at 52, I feel glamorous again."

Read the rest here:
Former air hostess says 5st weight loss cured her asthma as she reveals incredible transformation - The Sun